Multiple triggers across key markets may support Cipla's recent rally

In addition to the Q3 show, new launches offer upsides from current levels

A strong operational performance helped the country’s second-largest domestic drugmaker beat the Street estimates in the October-December quarter (third quarter, or Q3) of 2021-22. The top-line growth of 6 per cent was largely due to the India business growth of 12.9 per cent.

Growth in the domestic market, which accounts for 46 per cent of overall revenue, was led by its three key segments of branded prescription drugs, trade generics, and consumer health business.

Growth in the branded business was driven by product launches and offtake across key therapies.

Respiratory, anti-infectives, and cardiac therapies account for 70 per cent of Cipla’s domestic